Literature DB >> 12958218

Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis.

Melissa B Miller1, Peter H Gilligan.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 12958218      PMCID： PMC193835          DOI： 10.1128/JCM.41.9.4009-4015.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  37 in total

1.  Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.

Authors:  J L Burns; J M Van Dalfsen; R M Shawar; K L Otto; R L Garber; J M Quan; A B Montgomery; G M Albers; B W Ramsey; A L Smith
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

2.  Direct PCR detection of Burkholderia cepacia complex and identification of its genomovars by using sputum as source of DNA.

Authors:  Pavel Drevínek; Hana Hrbácková; Ondrej Cinek; Jana Bartosová; Otakar Nyc; Alexandr Nemec; Petr Pohunek
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

3.  Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis.

Authors:  Shawn D Aaron; Wendy Ferris; Karam Ramotar; Katherine Vandemheen; Francis Chan; Raphael Saginur
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

4.  Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis.

Authors:  J S Chen; K A Witzmann; T Spilker; R J Fink; J J LiPuma
Journal:  J Pediatr       Date:  2001-11       Impact factor: 4.406

5.  Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.

Authors:  Dieter Worlitzsch; Robert Tarran; Martina Ulrich; Ute Schwab; Aynur Cekici; Keith C Meyer; Peter Birrer; Gabriel Bellon; Jürgen Berger; Tilo Weiss; Konrad Botzenhart; James R Yankaskas; Scott Randell; Richard C Boucher; Gerd Döring
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

6.  PCR-based detection and identification of Burkholderia cepacia complex pathogens in sputum from cystic fibrosis patients.

Authors:  A McDowell; E Mahenthiralingam; J E Moore; K E Dunbar; A K Webb; M E Dodd; S L Martin; B C Millar; C J Scott; M Crowe; J S Elborn
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

7.  Six-year molecular analysis of Burkholderia cepacia complex isolates among cystic fibrosis patients at a referral center for lung transplantation.

Authors:  David G Heath; Kathy Hohneker; Charlene Carriker; Kelly Smith; Jonathan Routh; John J LiPuma; Robert M Aris; David Weber; Peter H Gilligan
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

8.  Evaluation of MicroScan Autoscan for identification of Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  Lisa Saiman; Jane L Burns; Davise Larone; Yunhua Chen; Elizabeth Garber; Susan Whittier
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

9.  Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis.

Authors:  Gavin R Graff; Jane L Burns
Journal:  Chest       Date:  2002-06       Impact factor: 9.410

Review 10.  Lung infections associated with cystic fibrosis.

Authors:  Jeffrey B Lyczak; Carolyn L Cannon; Gerald B Pier
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132
View more
  22 in total

1.  Antimicrobial activity of CHIR-090, an inhibitor of lipopolysaccharide biosynthesis, against the Burkholderia cepacia complex.

Authors:  Karin Bodewits; Christian R H Raetz; John R Govan; Dominic J Campopiano
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

2.  Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.

Authors:  Edith T Zemanick; Brandie D Wagner; J Kirk Harris; Jeffery S Wagener; Frank J Accurso; Scott D Sagel
Journal:  Pediatr Pulmonol       Date:  2010-06

3.  Compliance of clinical microbiology laboratories in the United States with current recommendations for processing respiratory tract specimens from patients with cystic fibrosis.

Authors:  Juyan Zhou; Elizabeth Garber; Manisha Desai; Lisa Saiman
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

4.  Superiority of molecular techniques for identification of gram-negative, oxidase-positive rods, including morphologically nontypical Pseudomonas aeruginosa, from patients with cystic fibrosis.

Authors:  Nele Wellinghausen; Juliane Köthe; Beate Wirths; Anja Sigge; Sven Poppert
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

5.  Whole-genome sequence of Chryseobacterium oranimense, a colistin-resistant bacterium isolated from a cystic fibrosis patient in France.

Authors:  Poonam Sharma; Sushim Kumar Gupta; Seydina M Diene; Jean-Marc Rolain
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

6.  Multicenter Observational Study on Factors and Outcomes Associated with Various Methicillin-Resistant Staphylococcus aureus Types in Children with Cystic Fibrosis.

Authors:  Marianne S Muhlebach; Sonya L Heltshe; Elena B Popowitch; Melissa B Miller; Valeria Thompson; Margaret Kloster; Thomas Ferkol; Wynton C Hoover; Michael S Schechter; Lisa Saiman
Journal:  Ann Am Thorac Soc       Date:  2015-06

7.  Novel pan-genomic analysis approach in target selection for multiplex PCR identification and detection of Burkholderia pseudomallei, Burkholderia thailandensis, and Burkholderia cepacia complex species: a proof-of-concept study.

Authors:  Chi-Chun Ho; Candy C Y Lau; Paolo Martelli; San-Yuen Chan; Cindy W S Tse; Alan K L Wu; Kwok-Yung Yuen; Susanna K P Lau; Patrick C Y Woo
Journal:  J Clin Microbiol       Date:  2010-12-22       Impact factor: 5.948

Review 8.  Burkholderia cepacia Complex Bacteria: a Feared Contamination Risk in Water-Based Pharmaceutical Products.

Authors:  Mariana Tavares; Mariya Kozak; Alexandra Balola; Isabel Sá-Correia
Journal:  Clin Microbiol Rev       Date:  2020-04-15       Impact factor: 26.132

9.  Evaluation of colistin susceptibility in multidrug-resistant clinical isolates from cystic fibrosis, France.

Authors:  S Biswas; J-C Dubus; M Reynaud-Gaubert; N Stremler; J-M Rolain
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-05-30       Impact factor: 3.267

10.  Outcomes and Treatment of Chronic Methicillin-Resistant Staphylococcus aureus Differs by Staphylococcal Cassette Chromosome mec (SCCmec) Type in Children With Cystic Fibrosis.

Authors:  Sonya L Heltshe; Lisa Saiman; Elena B Popowitch; Melissa B Miller; Margaret Kloster; Valeria Thompson; Thomas W Ferkol; Wynton C Hoover; Michael S Schechter; Marianne S Muhlebach
Journal:  J Pediatric Infect Dis Soc       Date:  2014-06-09       Impact factor: 3.164
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.